Project Grant R21AI186724
Award Date
5/22/25
Completion Date
4/30/27
Dollars Obligated
$220K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Washington, USA
Similar Awards
This $231,752 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research at the Fred Hutchinson Cancer Center in Seattle, Washington to investigate the in vivo innate immune response to HIV-1 infection. The key objectives are to: 1) identify the cellular sources of cytokines released during acute HIV-1 infection and determine how each cell type functionally impacts the...
This $812,810 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research at Emory University to generate highly differentiated natural killer (NK) cells and evaluate their synergistic effects with broadly neutralizing antibodies in reducing the SIV reservoir and establishing viral control in the absence of antiretroviral therapy (ART). The key objectives are to: 1) define...
This $217,350 Project Grant award was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The objective is to characterize the role and functional regulation of CD89+ natural killer (NK) cells in the mucosal tissues of both normal and SIV/SHIV-infected macaques, as well as investigate the therapeutic potential of autologous CD89+ NK cells for modulating SIV infection. The research aims to inform...
This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify the transcriptional regulators that control human natural killer (NK) cell function during viral infections such as human cytomegalovirus (HCMV). The $666,567 award, which runs from May 2025 to April 2030, will fund investigations into the mechanisms by which the transcription factor MEF2C...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $128,250.00 to support the development of anti-PD-1-targeted chimeric antigen receptor (CAR) and genetic circuit technologies to deplete viral reservoirs in a nonhuman primate model of lentiviral infection, with the goal of advancing efforts towards an HIV cure. The key objectives are to engineer a more specific and...
This Project Grant award, with a total funding amount of $243,713, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The objective of this research project is to determine the mechanisms by which HIV-infected macrophages resist antibody-dependent cellular cytotoxicity (ADCC) by natural killer (NK) cells, in contrast to the susceptibility of infected CD4+ T cells. The project aims to...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to generate highly differentiated natural killer (NK) cells that can synergize with broadly neutralizing antibodies to establish viral control in the absence of antiretroviral therapy (ART). The $799,017 award to Emory University seeks to: 1) define the function and distribution of NK cells in tissues from...
This federal Project Grant award of $142,908.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports research by the San Diego Biomedical Research Institute to examine how antibody glycosylation influences natural killer (NK) cell activity and antibody-dependent cellular cytotoxicity (ADCC) during HIV infection. The key research objectives are to determine how specific...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $186,408 to the University of Washington to enhance the persistence of CD4CAR T-cells for the treatment of HIV. The research aims to characterize and overcome the effects of soluble HIV antigen on CD4CAR T-cell function, as well as to extend the persistence of CD4CAR T-cells using the IL15 cytokine. The grant will...
DEEP SEQUENCING OF THE HIV LATENT RESERVOIR TO DISCERN MECHANISMS OF CLONAL PROLIFERATION AND HIV PERSISTENCE - PROJECT SUMMARY/ABSTRACT THE HIV LATENT RESERVOIR (LR) IS THE MAJOR BARRIER TO CURE OF HIV. THE PERSISTENCE OF THE LR IN BLOOD AND TISSUES IN PEOPLE LIVING WITH HIV (PLWH) DURING ART IS DUE TO CELLULAR PROLIFERATION OF INFECTED CELLS. THREE MECHANISMS ARE POSTULATED TO DRIVE INFECTED CELL PROLIFERATION: INTEGRATION OF THE PROVIRUS IN OR NEAR GENES ASSOCIATED WITH CANCER OR CELL...